

Advanced Cervical Cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/A3B90EB01566EN.html>

Date: September 2021

Pages: 60

Price: US\$ 2,500.00 (Single User License)

ID: A3B90EB01566EN

Abstracts

This report can be delivered to the clients within 3-5 business days

DelveInsight's, "Advanced Cervical Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Advanced Cervical Cancer Understanding

Advanced Cervical Cancer: Overview

Advanced cervical cancer means the cancer has spread from the cervix to another area of the body such as the lungs. Sometimes cancer is advanced when it is first diagnosed. Unfortunately advanced cancer can't usually be cured. But treatment might control it, help symptoms, and improve your quality of life for a while. The most common places for cervical cancer to spread is to the lymph nodes, liver, lungs and bones. Treatment for advanced cervical cancer depends on the size of the cancer and where it is in the body. Chemotherapy can be used to treat advanced cervical cancer. Some women may have an operation called pelvic exenteration for cervical cancer that has come back within the pelvis.

'Advanced Cervical Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Cervical Cancer pipeline landscape is provided which includes the disease overview and Advanced Cervical Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Cervical Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Cervical Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Cervical Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Cervical Cancer.

Advanced Cervical Cancer Emerging Drugs Chapters

This segment of the Advanced Cervical Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Cervical Cancer Emerging Drugs

Durvalumab: AstraZeneca

Durvalumab is a human immunoglobulin G1 kappa (IgG1?) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells. Currently, it is in Phase III stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.

Dostarlimab: GlaxoSmithKline

Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Currently, it is in Phase II stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.

Further product details are provided in the report.

Advanced Cervical Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Cervical Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Cervical Cancer

There are approx. 50+ key companies which are developing the therapies for Advanced Cervical Cancer. The companies which have their Advanced Cervical Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Advanced Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Cervical Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Cervical Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Cervical Cancer drugs.

Advanced Cervical Cancer Report Insights

- Advanced Cervical Cancer Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Advanced Cervical Cancer Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Advanced Cervical Cancer drugs?

How many Advanced Cervical Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Cervical Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Cervical Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Advanced Cervical Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AstraZeneca

GlaxoSmithKline

Human Genome Sciences Inc.

Advaxis

Bristol-Myers Squibb

Innovent Biologics

Hookipa Biotech GmbH

Shanghai Henlius Biotech

Biocad

Genexine, Inc.

Merck KGaA

Zeria Pharmaceutical

ISA Pharmaceuticals

Agenus Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Vaccibody AS

Pfizer

Fujifilm Pharmaceuticals U.S.A., Inc.

Karyopharm Therapeutics Inc

NETRIS Pharma

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Xencor, Inc.

Genmab

Sotio a.s.

Andes Biotechnologies

Rubius Therapeutics

Key Products

Durvalumab

Dostarlimab

Andes-1537

RTX-321

Mapatumumab

ADXS11-001

SO-C101

tisotumab vedotin

ISA101

Balstilimab

XmAb20717

SG001

NP137

Selinexor

FF-10850

TQ-B3525

PF-06939999

Z-100

M7824

VB10.16

GX-188E

BCD-100

Nivolumab

IBI310

HLX10

HB-201

Contents

Introduction

Executive Summary

Advanced Cervical Cancer: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Advanced Cervical Cancer – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Durvalumab: AstraZeneca

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Mid Stage Products (Phase II)

Comparative Analysis

Serplulimab: Henlix Biotech

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Early Stage Products (Phase I)

Comparative Analysis

RTX-321: Rubius Therapeutics

Product Description

Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Advanced Cervical Cancer Key Companies
Advanced Cervical Cancer Key Products
Advanced Cervical Cancer- Unmet Needs
Advanced Cervical Cancer- Market Drivers and Barriers
Advanced Cervical Cancer- Future Perspectives and Conclusion
Advanced Cervical Cancer Analyst Views
Advanced Cervical Cancer Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Advanced Cervical Cancer
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Advanced Cervical Cancer

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Advanced Cervical Cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A3B90EB01566EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A3B90EB01566EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970